Other advances in recent years include so-called targeted treatments that take aim at the underlying genetic mutations that fuel tumor growth drugs like Roche Holding AG's Zelboraf for melanoma.

WSJ: New Cancer Drugs Use Body's Own Defenses

Some of the companies that compete in these segment of health care incolde Bayer AG (BAYRY), Roche Holdings (RAHBY), and Abbott Laboratories (ABT).

FORBES: J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit